Drop in HPV Prevalence in 14- to 19-Year Olds in Vaccine Era
Prevalence of vaccine-type HPV decreased 56 percent from 2003-2006 to 2007-2010
TUESDAY, June 25 (HealthDay News) -- The prevalence of vaccine-type human papillomavirus (HPV) among 14- to 19-year old females decreased within four years of introduction of vaccination into routine immunization schedules in late 2006, according to research published online June 19 in the Journal of Infectious Diseases.
Lauri E. Markowitz, M.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues used data collected during the National Health and Nutrition Examination Surveys to analyze HPV prevalence from the prevaccine and vaccine eras (2003 to 2006 and 2007 to 2010). Prevalence was determined from cervicovaginal swab samples from 14- to 59-year-old females (4,150 samples in 2003 to 2006; 4,253 in the 2007 to 2010 period).
The researchers found that the prevalence of vaccine-type HPV (HPV-6, -11, -16, or -18) decreased by 56 percent, from 11.5 percent in 2003 to 2006 to 5.1 percent in 2007 to 2010, among 14- to 19-year-olds. There was no significant difference in prevalence between the two time periods for other age groups. The vaccine effectiveness was 82 percent for at least one dose.
"Our data suggest an early impact of HPV vaccination on vaccine type prevalence among females in the United States and a high vaccine effectiveness against vaccine type infection," the authors write. "This decline is encouraging, given the substantial health and economic burden of HPV-associated disease."
Abstract (http://jid.oxfordjournals.org/content/early/2013/06/18/infdis.jit192.abstract )Full Text (subscription or payment may be required) (http://jid.oxfordjournals.org/content/early/2013/06/18/infdis.jit192.full )